PERTH, Australia – Cellmid Ltd.'s lead anti-midkine antibody, CAB-102, reduced kidney injury and preserved renal function in a preclinical model of focal segmental glomerulosclerosis (FSGS), according to studies performed at the Westmead Institute in New South Wales.
PERTH, Australia – Following its IPO on Australia's Securities Exchange last year, radiopharma company Telix Pharmaceuticals Ltd. has been building global partnerships to prepare for a commercial build-up of its theranostic radiopharmaceuticals. To add to its arsenal, Telix has exercised an option to acquire Atlab Pharma SAS for $10 million to de-risk its prostate cancer monoclonal antibody (MAb), TLX-591.
PERTH, Australia – Cellmid Ltd.'s lead anti-midkine antibody, CAB-102, reduced kidney injury and preserved renal function in a preclinical model of focal segmental glomerulosclerosis (FSGS), according to studies performed at the Westmead Institute in New South Wales.
PERTH, Australia – After reporting positive data at the American Society of Clinical Oncology (ASCO) meeting for its Akt inhibitor in estrogen receptor (ER)-positive breast cancer, Melbourne-based Prescient Therapeutics Pty Ltd. is poised to carve out a niche for itself across a variety of cancers.
PERTH, Australia – After reporting positive data at the American Society of Clinical Oncology (ASCO) meeting for its Akt inhibitor in estrogen receptor (ER)-positive breast cancer, Melbourne-based Prescient Therapeutics Pty Ltd. is poised to carve out a niche for itself across a variety of cancers.
PERTH, Australia – Sydney-based Pharmaxis Ltd. announced a capital raising of A$24 million (US$17.3 million) to ready itself for another partnering play.
PERTH, Australia – Sydney-based Pharmaxis Ltd. announced a capital raising of A$24 million (US$17.3 million) to ready itself for another partnering play. The funds will be raised in a two-tranche placement of 73.4 million ordinary shares priced at A32 cents per share.
